ResearcherAsan Medical CenterNo recent work listed
Kyoungmin Lee
Matched on ORCID iD 0000-0002-6578-7671; OpenAlex author ID A5049646227. Sources: OpenAlex.
Their work
- Papers
- 2
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 19
2018: 1 paper · 2019: none · 2020: 1 paper
Papers 2
- Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.4143/crt.2019.190↗
- Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing. Co-author DOI 10.1007/s10637-017-0497-1↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Kyu‐pyo Kim · 2 shared papers, 2018–2020 · strength 0.16
- Paper Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Met… DOI 10.4143/crt.2019.190↗
- Paper Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category … DOI 10.1007/s10637-017-0497-1↗
- Do Hyun Park · 2 shared papers, 2018–2020 · strength 0.16
- Paper Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Met… DOI 10.4143/crt.2019.190↗
- Paper Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category … DOI 10.1007/s10637-017-0497-1↗
- Tae Jun Song · 2 shared papers, 2018–2020 · strength 0.16
- Paper Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Met… DOI 10.4143/crt.2019.190↗
- Paper Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category … DOI 10.1007/s10637-017-0497-1↗
- Myung‐Hwan Kim · 2 shared papers, 2018–2020 · strength 0.16
- Paper Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Met… DOI 10.4143/crt.2019.190↗
- Paper Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category … DOI 10.1007/s10637-017-0497-1↗
- Baek‐Yeol Ryoo · 2 shared papers, 2018–2020 · strength 0.16
- Paper Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Met… DOI 10.4143/crt.2019.190↗
- Paper Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category … DOI 10.1007/s10637-017-0497-1↗
- Changhoon Yoo · 2 shared papers, 2018–2020 · strength 0.16
- Paper Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Met… DOI 10.4143/crt.2019.190↗
- Paper Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category … DOI 10.1007/s10637-017-0497-1↗
- Sang Soo Lee · 2 shared papers, 2018–2020 · strength 0.16
- Paper Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Met… DOI 10.4143/crt.2019.190↗
- Paper Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category … DOI 10.1007/s10637-017-0497-1↗
- Inhwan Hwang · 1 shared paper, 2020 · strength 0.09
- Jin‐hong Park · 1 shared paper, 2020 · strength 0.09
- Kyunghye Bang · 1 shared paper, 2020 · strength 0.09
- Dongwook Oh · 1 shared paper, 2020 · strength 0.09
- Ki Byung Song · 1 shared paper, 2018 · strength 0.06
- Tae Won Kim · 1 shared paper, 2018 · strength 0.06
- Dae Wook Hwang · 1 shared paper, 2018 · strength 0.06
- Sang Hyun Shin · 1 shared paper, 2018 · strength 0.06
- W. Lee · 1 shared paper, 2018 · strength 0.06
- Dong Wan Seo · 1 shared paper, 2018 · strength 0.06
- Jae‐Lyun Lee · 1 shared paper, 2018 · strength 0.06
- Song Cheol Kim · 1 shared paper, 2018 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.